News summary

Carnyx Therapeutics Unveils Oral Sleep Candidate CNYX-005 with Preclinical Data Showing Increased NREM Sleep

Source: PR Newswire • Published: 14 Oct 2026, 10:00

Summarized by Masters of Longevity from PR Newswire.

A preview of a company press release presenting preclinical research on an oral sleep drug candidate and related leadership hire, useful for readers tracking early-stage sleep therapeutics.

Carnyx Therapeutics Unveils Oral Sleep Candidate CNYX-005 with Preclinical Data Showing Increased NREM Sleep
Key Takeaways
  • Aged rats given the oral candidate showed about a 1.5- to 2-hour increase in total sleep time compared to controls.
  • The observed sleep increase was driven primarily by boosted non-rapid eye movement sleep measured via continuous EEG.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.